強
強気
強気 · 25%SMMT
$32.18
シナリオ価格
$15.470
-0.079 (-0.51%)終値時点
Loading chart…
- 高値
- 15.550
- 始値
- 15.460
- 出来高加重平均価格
- 15.37
- 出来高
- 3.21M
- 時価総額
- 5.52B
- 安値
- 15.075
- 売買代金
- 49.33M
- EV/EBITDA（TTM）
- 0.00
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
AI分析 of Summit Therapeutics Inc (SMMT)
買いSummit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
アナリスト評価（6）
上値余地 +174.66%
買い
6 買い
0 中立
0 売り
現在: 15.47
安値
18.00
平均
42.49
高値
131.90
Barclays
Equal Weight
$20
2026-10-01
Barclays
2026-10-01
目標株価
$20
Equal Weight
Citi
買い
$43
2026-09-29
Citi
2026-09-29
目標株価
$43
買い
Jefferies
買い
$25
2026-09-09
Jefferies
2026-09-09
目標株価
$25
買い
Bernstein
Market Perform
—
2026-08-25
Bernstein
2026-08-25
目標株価
—
Market Perform
Leerink
Market Perform
$13
2026-08-12
Leerink
2026-08-12
目標株価
$13
Market Perform
バリュエーション指標
Summit Therapeutics Inc（SMMT）の現在の予想PERは3.72で、5年平均は-20.33です。
Alphio AI による SMMT の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
SMMT を保有するクジラ
イベントタイムライン
ニュース
9.010-25NewsfilterFirst Regimen to Significantly Improve Survival in Biliary Tract Cancer
7.510-24PRnewswireLunit Partners with Summit for AI Pathology Research
- 7.510-24Newsfilter
Lunit and Summit Announce Research Agreement for AI Pathology in Immuno-Oncology
- 7.510-23Newsfilter
Summit and Lunit Announce Research Agreement for AI Pathology Analysis
- 9.010-22Newsfilter
Ivonescimab Clinical Data to Feature at ESMO 2026
SMMT のよくある質問 — Alphio AI が回答
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Summit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
6 analysts cover SMMT: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 42.49.
コミュニティ
もっと見る ↗
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
もっと見る
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
もっと見る
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
もっと見る本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。